


Stereochemistry abstracts

Maria da Graça Nascimento,* Sandra P. Zanotto, Sílvia P. Melegari,
Luciano Fernandes and Marcus Mandolesi Sá

Tetrahedron: Asymmetry 14 (2003) 3111



Methyl (R)-3-acetoxy-2-methylenebutanoate

E.e. >99%



[α]_D²⁵ = +18.0 (*c* 5.0, CHCl₃)

Source of chirality: lipase-catalyzed resolution

Absolute configuration: (R)

Andrei Y. Khimiuk, Alexei V. Korenniykh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



D-Phenylglycyl-glycine


[α]_D²⁰ = -123.2 (*c* 1, 2.5 M HCl)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: *R*

Andrei Y. Khimiuk, Alexei V. Korenniykh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



(R)-3-Phenylpiperazine-2,5-dione


[α]_D²⁰ = -74.2 (*c* 1, DMSO)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: *R*

Andrei Y. Khimiuk, Alexei V. Korenniykh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



D-Phenylglycyl-L-alanine


[α]_D²⁰ = -119.8 (*c* 1, 2.5 M HCl)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (2S,5R)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



C₁₂H₁₆N₂O₃
D-Phenylglycyl-L-alanine methyl ester


[α]_D²⁰ = -118.4 (c 1, EtOH)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (2S,5R)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



C₁₁H₁₂N₂O₂
(3S,6R)-3-Methyl-6-phenylpiperazine-2,5-dione


[α]_D²⁰ = -57.2 (c 1, DMSO)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (3S,6R)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



C₁₃H₁₈N₂O₃
D-Phenylglycyl-L-valine


[α]_D²⁰ = -75.6 (c 1, 2.5 M HCl)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (2S,5R)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



C₁₄H₂₀N₂O₃
D-Phenylglycyl-L-valine methyl ester


[α]_D²⁰ = -77.0 (c 1, EtOH)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (2S,5R)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



(3*S*,6*R*)-3-isopropyl-6-phenylpiperazine-2,5-dione



$[\alpha]_D^{20} = -61.4$ (*c* 1, DMSO)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (3*S*,6*R*)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



D-Phenylglycyl-L-leucine



$[\alpha]_D^{20} = -95.2$ (*c* 1, 2.5 M HCl)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (2*S*,5*R*)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



D-Phenylglycyl-L-leucine methyl ester


$[\alpha]_D^{20} = -94.0$ (*c* 1, EtOH)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (2*S*,5*R*)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



(3*S*,6*R*)-3-(2-methylpropyl)-6-phenylpiperazine-2,5-dione


$[\alpha]_D^{20} = -47.0$ (*c* 1, DMSO)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (3*S*,6*R*)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



D-Phenylglycyl-L-isoleucine


[α]_D²⁰ = -68.8 (c 0.5, 2.5 M HCl)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (2S,5R)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



D-Phenylglycyl-L-isoleucine methyl ester


[α]_D²⁰ = -76.8 (c 1, EtOH)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (2S,5R)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



D-Phenylglycyl-L-phenylalanine



[α]_D²⁰ = -25.4 (c 1, 2.5 M HCl)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (2S,5R)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



D-Phenylglycyl-L-phenylalanine methyl ester


[α]_D²⁰ = -40.2 (c 1, EtOH)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (2S,5R)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



(3*R*,6*S*)-3-Phenyl-6-(phenylmethyl)piperazine-2,5-dione


$[\alpha]_D^{20} = -17.4$ (*c* 1, DMSO)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (3*R*,6*S*)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



D-Phenylglycyl-L-tryptophan


$[\alpha]_D^{20} = -72.8$ (*c* 1, 2.5 M HCl)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (2*S*,5*R*)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123



(3*S*,6*R*)-3-(1*H*-Indol-3-ylmethyl)-6-phenylpiperazine-2,5-dione


$[\alpha]_D^{20} = -34.8$ (*c* 1, DMSO)

Source of chirality: starting materials and enzymatic reaction

Absolute configuration: (3*S*,6*R*)

Andrei Y. Khimiuk, Alexei V. Korennikh, Luuk M. van Langen,
Fred van Rantwijk, Roger A. Sheldon and Vytas K. Švedas*

Tetrahedron: Asymmetry 14 (2003) 3123





(3*S*,6*R*)-3-(1*H*-Imidazol-4-ylmethyl)-6-phenylpiperazine-2,5-dione


$[\alpha]_D^{20} = -40.6$ (*c* 1, DMSO)

Source of chirality: starting materials and enzymatic reaction


Absolute configuration: (3*S*,6*R*)

(R,R)- α,α' -Bis(trifluoromethyl)-10,10'-(9,9'-bianthryl)dimethanol $[\alpha]_D^{25} = -50.5$ (*c* 1.9, CH_2Cl_2)2-(α -Methylbenzyliminomethyl)-4,5-dimethyl-3,6-diphenyl-1-phosphabicyclo[2.2.1]hepta-2,5-diene $Ee = 100\%$ $[\alpha]_D^{20} -252.0$ (*c* 1.0, $CHCl_3$)

Source of chirality: chiral substrates

Absolute configuration: (*R*)_P, (*R*)_C2-(α -Methylbenzyliminomethyl)-4,5-dimethyl-3,6-diphenyl-1-phosphabicyclo[2.2.1]hepta-2,5-diene $Ee = 100\%$ $[\alpha]_D^{20} +119.0$ (*c* 1.0, CH_2Cl_2)

Source of chirality: chiral substrates


Absolute configuration: (*S*)_P, (*R*)_C

2-(Phenyliminomethyl)-4,5-dimethyl-3,6-diphenyl-1-phosphabicyclo[2.2.1]hepta-2,5-diene

 $Ee = 100\%$ $[\alpha]_D^{20} -126.1$ (*c* 1.0, acetone)

Source of chirality: chiral substrates

Absolute configuration: (*R*)_P




2-(*tert*-Butyliminomethyl)-4,5-dimethyl-3,6-diphenyl-1-phosphabicyclo[2.2.1]hepta-2,5-diene

Ee = 100%

$[\alpha]_D^{20} -158.0$ (*c* 0.9, CHCl₃)

Source of chirality: chiral substrates

Absolute configuration: (*R*)_P




2-(Benzylaminomethyl)-4,5-dimethyl-3,6-diphenyl-1-phosphabicyclo[2.2.1]hepta-2,5-diene

Ee = 100%

$[\alpha]_D^{20} -135$ (*c* 0.9, CH₂Cl₂)

Source of chirality: chiral substrates

Absolute configuration: (*R*)_P




2-(α -Methylbenzylaminomethyl)-4,5-dimethyl-3,6-diphenyl-1-phosphabicyclo[2.2.1]hepta-2,5-diene

Ee = 100%

$[\alpha]_D^{20} -125$ (*c* 1.1, CH₂Cl₂)

Source of chirality: chiral substrates

Absolute configuration: (*R*)_P, (*R*)_C




Ethyl (2*S*,4*R*)-1-benzyl-4-hydroxyprolinate

$[\alpha]_D^{20} = -56.3$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*




Ethyl (2S,4R)-1-benzyl-4-(4-methylphenylsulfonyloxy)prolinate

 $[\alpha]_D^{20} = -13.8$ (*c* 0.99, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2S,4R




Ethyl (2S,4S)-4-acetoxy-1-benzylprolinate

 $[\alpha]_D^{20} = -55.0$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2S,4S




Ethyl (2S,4S)-1-benzyl-4-hydroxyprolinate

 $[\alpha]_D^{20} = -38.2$ (*c* 0.99, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2S,4S




Ethyl (2R,4R)-1-benzyl-4-(4-methylphenylsulfonyloxy)prolinate


 $[\alpha]_D^{20} = +39.2$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 2R,4R

 $C_{16}H_{21}NO_4$ Ethyl (2*R*,4*S*)-4-acetoxy-1-benzylproline $[\alpha]_D^{20} = +36.6$ (*c* 1.0, CHCl₃)


Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S* $C_{18}H_{31}NO_2Si$ (3*R*,5*S*)-1-Benzyl-5-(*tert*-butyldimethylsilyloxy)methylpyrrolidin-3-ol $[\alpha]_D^{20} = -46.0$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 3*R*,5*S* $C_{19}H_{30}N_2OSi$ (3*S*,5*S*)-1-Benzyl-5-(*tert*-butyldimethylsilyloxy)methylpyrrolidine-3-carbonitrile $[\alpha]_D^{20} = -67.5$ (*c* 0.07, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*S*,5*S* $C_{18}H_{30}N_4OSi$ (2*S*,4*S*)-4-Azido-1-benzyl-2-(*tert*-butyldimethylsilyloxy)methylpyrrolidine $[\alpha]_D^{20} = -79.0$ (*c* 0.3, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*S*


 $C_{15}H_{18}N_2O_2$

Ethyl (2S,4S)-1-benzyl-4-cyanoprolinate

 $[\alpha]_D^{20} = -17.9$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2S,4S


 $C_{14}H_{18}N_4O_2$

Ethyl (2S,4S)-4-azido-1-benzylprolinate

 $[\alpha]_D^{20} = -57.5$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2S,4S


 $C_{13}H_{20}N_2O$

(2S,4R)-(4-Aminomethyl-1-benzylpyrrolidin-2-yl)methanol

 $[\alpha]_D^{20} = -30.7$ (*c* 0.27, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2S,4R


 $C_{12}H_{18}N_2O$

(2S,4S)-(4-Amino-1-benzylpyrrolidin-2-yl)methanol

 $[\alpha]_D^{20} = -14.2$ (*c* 0.5, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2S,4S




$C_{15}H_{18}N_2O_2$
Ethyl (2*S*,4*R*)-1-benzyl-4-cyanoprolinate

$[\alpha]_D^{20} = -64.8$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*




$C_{14}H_{18}N_4O_2$
Ethyl (2*S*,4*R*)-4-azido-1-benzylprolinate

$[\alpha]_D^{20} = -53.2$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*




$C_{13}H_{20}N_2O$
(2*S*,4*S*)-(4-Aminomethyl-1-benzylpyrrolidin-2-yl)methanol

$[\alpha]_D^{20} = +27.9$ (*c* 0.96, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*S*




$C_{12}H_{18}N_2O$
(2*S*,4*R*)-(4-Amino-1-benzylpyrrolidin-2-yl)methanol

$[\alpha]_D^{20} = -65.8$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*




$C_{13}H_{15}NO_4 \times HCl$
(2*S*,4*R*)-1-Benzylpyrrolidine-2,4-dicarboxylic acid hydrochloride

$[\alpha]_D^{20} = +29.4$ (*c* 0.78, MeOH)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*




$C_{21}H_{26}ClN_3O_3$
(3*S*,5*R*)-*N*-(1-Benzyl-5-hydroxymethyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide

$[\alpha]_D^{20} = +64.4$ (*c* 0.15, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*S*,5*R*




$C_{21}H_{26}ClN_3O_3$
(3*S*,5*S*)-*N*-(1-Benzyl-5-hydroxymethyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide

$[\alpha]_D^{20} = +42.3$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*S*,5*S*




$C_{22}H_{28}ClN_3O_3$
(3*R*,5*S*)-*N*-(1-Benzyl-5-hydroxymethyl-3-pyrrolidinylmethyl)-5-chloro-2-methoxy-4-methylaminobenzamide

$[\alpha]_D^{20} = -35.6$ (*c* 0.32, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 3*R*,5*S*

 $C_{22}H_{28}ClN_3O_3$


(3R,5R)-N-(1-Benzyl-5-hydroxymethyl-3-pyrrolidinylmethyl)-5-chloro-2-methoxy-4-methylaminobenzamide

 $[\alpha]_D^{20} = +30.1$ (*c* 0.05, CHCl₃)


Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*R* $C_{22}H_{26}ClN_3O_4$ (3*S*,5*S*)-4-Acetylamino-N-(1-benzyl-5-hydroxymethyl-3-pyrrolidinyl)-5-chloro-2-methoxybenzamide $[\alpha]_D^{20} = +60.1$ (*c* 0.23, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 3*S*,5*S* $C_{23}H_{28}ClN_3O_4$ (3*R*,5*S*)-4-Acetylamino-N-(1-benzyl-5-hydroxymethyl-3-pyrrolidinyl)-5-chloro-2-methoxybenzamide $[\alpha]_D^{20} = -52.0$ (*c* 0.03, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*S* $C_{23}H_{28}ClN_3O_4$ (3*S*,5*S*)-4-(*N*-Acetyl-*N*-methylamino)-N-(1-benzyl-5-hydroxymethyl-3-pyrrolidinyl)-5-chloro-2-methoxybenzamide $[\alpha]_D^{20} = +11.5$ (*c* 0.82, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*S*,5*S*




$C_{12}H_{16}N_2O_2$
(2*S*,4*R*)-1-Benzyl-4-hydroxypyrrolidine-2-carboxamide

$[\alpha]_D^{20} = -79.6$ (*c* 1.0, $CHCl_3$)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*




$C_{12}H_{17}NO_2$
(3*R*,5*S*)-1-Benzyl-5-hydroxymethylpyrrolidin-3-ol

$[\alpha]_D^{20} = -58.4$ (*c* 1.0, $CHCl_3$)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*S*




$C_{20}H_{33}NO_3Si$
Ethyl (2*S*,4*R*)-1-benzyl-4-(*tert*-butyldimethylsilyloxy)prolinate

$[\alpha]_D^{20} = -41.0$ (*c* 1.0, $CHCl_3$)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*




$C_{18}H_{31}NO_2Si$
(3*R*,5*S*)-1-Benzyl-3-(*tert*-butyldimethylsilyloxy)-5-hydroxymethylpyrrolidin

$[\alpha]_D^{20} = -36.5$ (*c* 1.0, $CHCl_3$)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*S*




$C_{13}H_{16}N_2O$
(2*S*,4*R*)-(1-Benzyl-4-hydroxypyrrolidin-2-yl)acetonitrile

$[\alpha]_D^{20} = -67.1$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*




$C_{13}H_{16}N_2O$
(3*R*,5*R*)-1-Benzyl-5-hydroxypiperidine-3-carbonitrile

$[\alpha]_D^{20} = -7.0$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*R*




$C_{19}H_{30}N_2OSi$
(2*S*,4*R*)-[1-Benzyl-4-(*tert*-butyldimethylsilyloxy)pyrrolidin-2-yl]acetonitrile

$[\alpha]_D^{20} = -41.0$ (*c* 0.63, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*




$C_{19}H_{30}N_2OSi$
(3*R*,5*R*)-1-Benzyl-5-(*tert*-butyldimethylsilyloxy)piperidin-3-carbonitrile

$[\alpha]_D^{20} = +18.4$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*R*




$C_{12}H_{18}N_2O$
(3*R*,5*S*)-5-Aminomethyl-1-benzylpyrrolidin-3-ol

$[\alpha]_D^{20} = -54.6$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*S*




$C_{19}H_{34}N_2OSi$
(2*S*,4*R*)-2-[1-Benzyl-4-(*tert*-butyldimethylsilyloxy)pyrrolidin-2-yl]ethylamine

$[\alpha]_D^{20} = -68.0$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*




$C_{12}H_{17}NO_2$
(3*R*,5*R*)-1-Benzyl-5-hydroxymethylpyrrolidin-3-ol

$[\alpha]_D^{20} = +35.8$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*R*




$C_{20}H_{33}NO_3Si$
Ethyl (2*R*,4*R*)-1-benzyl-4-(*tert*-butyldimethylsilyloxy)proline


$[\alpha]_D^{20} = +42.0$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 2*R*,4*R*

 $C_{18}H_{31}NO_2Si$ (3*R*,5*R*)-1-Benzyl-3-(*tert*-butyldimethylsilyloxy)-5-hydroxymethylpyrrolidin $[\alpha]_D^{20} = +46.2$ (*c* 1.0, CHCl₃)


Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*R* $C_{12}H_{16}N_2O_2$ (2*R*,4*R*)-1-Benzyl-4-hydroxypyrrolidine-2-carboxamide $[\alpha]_D^{20} = +39.6$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 2*R*,4*R* $C_{18}H_{27}NO_2$ Ethyl (2*R*,4*S*)-1-benzyl-4-butylprolinate $[\alpha]_D^{20} = +59.0$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S* $C_{14}H_{19}NO_2$ Ethyl (2*S*)-2-benzylaminopent-4-enoate $[\alpha]_D^{20} = -18.0$ (*c* 0.28, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 2*S*

 $C_{15}H_{21}NO_2$ Ethyl (2*R*,4*S*)-1-benzyl-4-methylproline $[\alpha]_D^{20} = +48.7$ (*c* 1.0, CHCl₃)


Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S* $C_{15}H_{21}NO_2$ Ethyl (2*S*,4*S*)-1-benzyl-4-methylproline $[\alpha]_D^{20} = -43.2$ (*c* 0.04, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 2*S*,4*S* $C_{27}H_{39}NO_4S$ (2*S*,4*R*)-1-Benzyl-5-(1-butyl-1-hydroxypentyl)pyrrolidin-3-yl tosylate $[\alpha]_D^{20} = -28.8$ (*c* 0.8, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R* $C_{24}H_{41}NO$ (2*R*,4*S*)-5-(1-Benzyl-4-butylpyrrolidin-2-yl)nonan-5-ol $[\alpha]_D^{20} = +16.1$ (*c* 0.32, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*




$C_{21}H_{27}NO_4S$
(*3R,5S*)-1-Benzyl-5-(1-hydroxy-1-methylethyl)pyrrolidin-3-yl tosylate

$[\alpha]_D^{20} = -26.1$ (*c* 0.23, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*S*




$C_{15}H_{21}NO_2$
(*3R,5R*)-5-Aminomethyl-1-benzylpyrrolidin-3-ol

$[\alpha]_D^{20} = +30.3$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*R*




$C_{16}H_{24}N_2O$
(*2R,4S*)-1-Benzyl-4-butylpyrrolidine-2-carboxamide

$[\alpha]_D^{20} = +82.3$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*




$C_{13}H_{18}N_2O$
(*2R,4S*)-1-Benzyl-4-methylpyrrolidine-2-carboxamide


$[\alpha]_D^{20} = +74.9$ (*c* 0.7, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 2*R*,4*S*

(2*R*,4*S*)-(1-Benzyl-4-butylpyrrolidin-2-yl)methanol $[\alpha]_D^{20} = +78.0$ (*c* 1.0, CHCl₃)


Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*(3*R*,5*R*)-1-Benzyl-5-(*tert*-butyldimethylsilyloxy)methylpyrrolidin-3-yl tosylate $[\alpha]_D^{20} = +76.7$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 3*R*,5*R*(3*R*,5*R*)-1-Benzyl-5-hydroxymethylpyrrolidin-3-yl tosylate $[\alpha]_D^{20} = +38.9$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*R*(2*R*,4*S*)-1-Benzyl-4-methylpyrrolidin-2-carboxylic acid hydrochloride $[\alpha]_D^{20} = +33.9$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*




$C_{14}H_{18}INO_2$
Ethyl (2*S*,4*R*)-1-benzyl-4-iodoprolinate

$[\alpha]_D^{20} = -62.1$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*




$C_{14}H_{18}INO_2$
Ethyl (2*S*,4*S*)-1-benzyl-4-iodoprolinate

$[\alpha]_D^{20} = -20.9$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*S*




$C_{13}H_{16}N_2O$
(2*R*,4*R*)-(1-Benzyl-4-hydroxypyrrolidin-2-yl)acetonitrile

$[\alpha]_D^{20} = +40.3$ (*c* 0.3, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*R*




$C_{13}H_{16}N_2O$
(3*S*,5*R*)-1-Benzyl-5-hydroxypiperidine-3-carbonitrile

$[\alpha]_D^{20} = +17.3$ (*c* 0.13, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*S*,5*R*




C₁₆H₂₆N₂
(2*R*,4*S*)-1-Benzyl-4-butylpyrrolidin-2-yl)methylamine

[α]_D²⁰ = +84.0 (*c* 0.08, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*




C₁₂H₁₆ClNO×HCl
(3*R*,5*S*)-1-Benzyl-5-chloromethylpyrrolidin-3-ol hydrochloride

[α]_D²⁰ = +2.3 (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*S*




C₁₇H₂₄N₂
(2*R*,4*S*)-(1-Benzyl-4-butylpyrrolidin-2-yl)acetonitrile

[α]_D²⁰ = +41.4 (*c* 0.1, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*




C₁₄H₁₈N₂
(2*R*,4*S*)-(1-Benzyl-4-methylpyrrolidin-2-yl)acetonitrile

[α]_D²⁰ = -72.6 (*c* 0.6, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*




C₁₃H₂₀N₂
(2*R*,4*S*)-(1-Benzyl-4-methylpyrrolidin-2-yl)methylamine

[α]_D²⁰ = +70.4 (*c* 0.13, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*




C₁₉H₃₃NOSi
(2*R*,4*S*)-1-Benzyl-2-(*tert*-butyldimethylsilyloxy)methyl-4-methylpyrrolidine

[α]_D²⁰ = +63.2 (*c* 0.85, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*




C₂₁H₃₇NOSi
(2*R*,4*S*)-1-Benzyl-2-(*tert*-butyldimethylsilyloxy)methyl-4-propylpyrrolidine

[α]_D²⁰ = +39.5 (*c* 0.41, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*




C₁₆H₂₄ClN×HCl
(2*R*,4*S*)-1-Benzyl-4-butyl-2-chloromethylpyrrolidine hydrochloride

[α]_D²⁰ = +24.8 (*c* 0.61, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*




$C_{16}H_{23}NO_2 \times HCl$
(2*R*,4*S*)-1-Benzyl-4-butylpyrrolidin-2-ylcarboxylic acid hydrochloride

$[\alpha]_D^{20} = +37.1$ (*c* 0.85, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*




$C_{13}H_{17}NO_3 \times HCl$
(3*R*,5*R*)-1-Benzyl-5-hydroxypiperidine-3-ylcarboxylic acid hydrochloride

$[\alpha]_D^{20} = -0.2$ (*c* 2.68, MeOH)

Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*R*




$C_{19}H_{30}N_2OSi$
(2*R*,4*R*)-[1-Benzyl-4-(*tert*-butyldimethylsilyloxy)pyrrolidin-2-yl]acetonitrile

$[\alpha]_D^{20} = +35.3$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*R*




$C_{13}H_{19}NO$
(2*R*,4*S*)-(1-Benzyl-4-methylpyrrolidin-2-yl)methanol


$[\alpha]_D^{20} = +63.5$ (*c* 1.0, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 2*R*,4*S*

 $C_{12}H_{16}NOCl \times HCl$ (3*R*,5*R*)-1-Benzyl-5-chloromethylpyrrolidin-3-ol hydrochloride $[\alpha]_D^{20} = +8.8$ (*c* 0.1, CHCl₃)


Source of chirality: natural amino acid

Absolute configuration: 3*R*,5*R* $C_{19}H_{34}N_2OSi$ (3*S*,5*R*)-[1-Benzyl-5-(*tert*-butyldimethylsilyloxy)piperidin-3-yl]methylamine $[\alpha]_D^{20} = +42.2$ (*c* 0.32, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 3*S*,5*R* $C_{21}H_{26}ClN_3O_3$ (2*S*,4*R*)-N-[(1-Benzyl-4-hydroxypyrrolidin-2-yl)methyl]-5-chloro-2-methoxy-4-methylaminobenzamide $[\alpha]_D^{20} = -122.2$ (*c* 0.09, CHCl₃)

Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R* $C_{21}H_{26}ClN_3O_3$ (2*R*,4*R*)-N-[(1-Benzyl-4-hydroxypyrrolidin-2-yl)methyl]-5-chloro-2-methoxy-4-methylaminobenzamide $[\alpha]_D^{20} = +47.2$ (*c* 0.62, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 2*R*,4*R*



(2R,4S)-N-[(1-Benzyl-4-butylpyrrolidin-2-yl)methyl]-5-chloro-2-methoxy-4-methylaminobenzamide

 $[\alpha]_D^{20} = +89.5$ (*c* 0.29, CHCl₃)


Source of chirality: natural amino acid

Absolute configuration: 2*R*,4*S*

(2S,4R)-N-[2-(1-Benzyl-4-hydroxypyrrolidin-2-yl)ethyl]-5-chloro-2-methoxy-4-methylaminobenzamide

 $[\alpha]_D^{20} = -36.8$ (*c* 0.13, CHCl₃)



Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R*

(2R,4S)-N-[(1-Benzyl-4-methylpyrrolidin-2-yl)methyl]-5-chloro-2-methoxy-4-methylaminobenzamide

 $[\alpha]_D^{20} = +48.4$ (*c* 0.15, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 2*R*,4*S*

(2R,4S)-N-[(1-Benzyl-4-butylpyrrolidin-2-yl)ethyl]-5-chloro-2-methoxy-4-methylaminobenzamide


 $[\alpha]_D^{20} = +84.0$ (*c* 0.19, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 2*R*,4*S*

 $C_{22}H_{28}ClN_3O_3$ (2S,4R)-*N*-[2-(1-Benzyl-4-hydroxypyrrolidin-2-yl)ethyl]-5-chloro-2-methoxy-4-methylaminobenzamide $[\alpha]_D^{20} = +40.0$ (*c* 0.05, CHCl₃)


Source of chirality: natural amino acid

Absolute configuration: 2*S*,4*R* $C_{22}H_{28}ClN_3O_2$ (2*R*,4*S*)-*N*-[(1-Benzyl-4-methylpyrrolidin-2-yl)methyl]-5-chloro-2-methoxy-4-methylaminobenzamide $[\alpha]_D^{20} = +69.5$ (*c* 0.1, CHCl₃)

Source of chirality: natural amino acid


Absolute configuration: 2*R*,4*S* $C_{25}H_{29}N_3O_2$ (1*R*,4*R*,4*'R*,5*'R*)-4*',5'*-Diphenylspiro[7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]hept-5-en-2,2'-imidazolidine]Ee $\geq 97\%$ (chiral diamine) $[\alpha]_D^{25} = +19$ (*c* 0.5, CHCl₃)

Source of chirality: resolution

Absolute configuration: (1*R*,4*R*,4*'R*,5*'R*) $C_{25}H_{29}N_3O_2$ (1*S*,4*S*,4*'R*,5*'R*)-4*',5'*-Diphenylspiro[7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]hept-5-en-2,2'-imidazolidine]Ee $\geq 97\%$ (chiral diamine) $[\alpha]_D^{25} = +60$ (*c* 1.5, CHCl₃)

Source of chirality: resolution

Absolute configuration: (1*S*,4*S*,4*'R*,5*'R*)




$C_{11}H_{15}NO_3$
(1*R*,4*R*)-7-(*tert*-Butoxycarbonyl)-7-azabicyclo[2.2.1]hept-5-en-2-one

Ee $\geq 97\%$ (chiral diamine)
 $[\alpha]_D^{25} = -360$ (*c* 0.25, CHCl₃)
 Source of chirality: resolution
 Absolute configuration: (1*R*,4*R*)



$C_{11}H_{15}NO_3$
(1*S*,4*S*)-7-(*tert*-Butoxycarbonyl)-7-azabicyclo[2.2.1]hept-5-en-2-one

Ee $\geq 97\%$ (chiral diamine)
 $[\alpha]_D^{25} = +384$ (*c* 0.9, CHCl₃)
 Source of chirality: resolution
 Absolute configuration: (1*S*,4*S*)




$C_{11}H_{17}NO_3$
(1*S*,4*R*)-7-(*tert*-Butoxycarbonyl)-7-azabicyclo[2.2.1]heptan-2-one

Ee $\geq 97\%$ (chiral diamine)
 $[\alpha]_D^{25} = +74$ (*c* 1.0, CHCl₃)
 Source of chirality: resolution
 Absolute configuration: (1*S*,4*R*)




$C_{11}H_{17}NO_3$
(1*R*,4*S*)-7-(*tert*-Butoxycarbonyl)-7-azabicyclo[2.2.1]heptan-2-one


Ee $\geq 97\%$ (chiral diamine)
 $[\alpha]_D^{25} = -73$ (*c* 1.0, CHCl₃)
 Source of chirality: resolution
 Absolute configuration: (1*R*,4*S*)

 $C_{16}H_{28}O_3$ (1*R*,2*S*,5*R*)-(-)-Menthyl 2-oxo-hexanoate

E.e. = 99%

 $[\alpha]_D = -64.6$ ($c = 2.34$, EtOH)Source of chirality: (1*R*,2*S*,5*R*)-(-)-menthol $C_{16}H_{26}O_3$ (1*R*)-(+)-endo-Fenchyl 2-oxo-hexanoate

E.e. = 96%


 $[\alpha]_D = +33.8$ ($c = 0.34$, EtOH)Source of chirality: (1*R*)-(+)-*endo*-fenchyl alcohol $C_{14}H_{18}O_3$

(R)-(+)-1-Phenylethyl 2-oxo-hexanoate

E.e. >99%

 $[\alpha]_D = +2.2$ ($c = 1.08$, CH_2Cl_2)

Source of chirality: (R)-(+)-1-phenylethanol


 $C_{15}H_{20}O_3$

(R)-(-)-(2-Methoxy-1-phenyl)ethyl 2-oxo-hexanoate

E.e. >99%

 $[\alpha]_D = -55.4$ ($c = 1.3$, EtOH)

Source of chirality: (R)-(-)-2-methoxy-1-phenylethanol


 $C_{23}H_{36}O_3$

(R)-(-)-1-(2,4,6-Triisopropylphenyl)ethyl 2-oxo-hexanoate

E.e. = 100%

 $[\alpha]_D = -25.6$ ($c = 1.7$, CH_2Cl_2)

Source of chirality: (R)-(-)-1-(2,4,6-triisopropylphenyl)ethanol


 $C_{23}H_{26}O_3$

(S)-(+)2,2-Diphenylcyclohexyl 2-oxo-hexanoate

E.e. >97%

 $[\alpha]_D = +117.9$ ($c = 1.1$, EtOH)

Source of chirality: (S)-2,2-diphenylcyclohexanol


 $C_{18}H_{24}O_3$

(1R,2S)-(-)-trans-2-Phenyl-1-cyclohexyl 2-oxo-hexanoate

E.e. >98%

 $[\alpha]_D = -41.8$ ($c = 1.41$, EtOH)

Source of chirality: (1R,2S)-(-)-trans-2-phenyl-1-cyclohexanol


 $C_{18}H_{20}O_3$

(S)-(-)-1-(2-Naphthyl)ethyl 2-oxo-hexanoate

E.e. >99%

 $[\alpha]_D = -39.3$ ($c = 1.37$, CH_2Cl_2)

Source of chirality: (S)-(-)-1-(2-naphthyl)ethanol


 $C_{20}H_{30}O_3$

(R)-(+)-1-(2,4,6-Triisopropylphenyl)ethyl 2-oxo-propanoate

E.e. = 97%

 $[\alpha]_D^{23} = +20.6$ ($c = 2.7$, CH_2Cl_2)

Source of chirality: (R)-(+)-1-(2,4,6-triisopropylphenyl)ethanol


 $C_{18}H_{24}O_3$

(1R,2S,5R)-(-)-Menthyl 2-oxo-phenylacetate

E.e. = 99%

 $[\alpha]_D^{23} = -54.9$ ($c = 1.38$, CH_2Cl_2)


Source of chirality: (1R,2S,5R)-(-)-menthol

 $C_{14}H_{17}O_4Br$ Methyl 4-O-benzoyl-6-bromo-2,3,6-trideoxy- β -D-*erythro*-hexopyranoside $[\alpha]_D^{23} = +14.6$ ($c = 1.0$, $CHCl_3$)

E.e. = 100%

Source of chirality: tri-O-acetyl-D-glucal


Absolute configuration: 1S,4S,5S

 $C_{28}H_{38}O_6$ Methyl 3,4-di-O-2,6-dideoxy-3-C-methyl- α -L-xylo-hexopyranosyl-(1 \rightarrow 4)-2,3,6-trideoxy- α -D-*erythro*-hexopyranoside $[\alpha]_D^{23} = -63$ ($c = 0.33$, $CHCl_3$)

E.e. = 100%

Source of chirality: tri-O-acetyl-D-glucal and 2-deoxy-D-ribose

Absolute configuration: 1S,4S,5R,1'S,3'R,4'R,5'S




Methyl 2,6-dideoxy-3-C-methyl- α -L-xylo-hexopyranosyl-(1 \rightarrow 4)-2,3,6-trideoxy- α -D-erythro-hexopyranoside

$[\alpha]_D^{23} = +44.7$ (c 0.94, $CHCl_3$)

E.e. = 100%

Source of chirality: tri-O-acetyl-D-glucal and
2-deoxy-D-ribose

Absolute configuration: 1S,4S,5R,1'S,3'R,4'R,5'S




N-Formyl-D-allo-isoleucine methyl ester

D.e. = 98% (HPLC)

$[\alpha]_D^{20} = -32.5$ (c 1, $CHCl_3$)

Source of chirality: enzymatic diastereoselective
hydrolysis

Absolute configuration: (2R,3R)




N-Formyl-D-allo-isoleucine chloroethyl ester

D.e. = 96% (HPLC)

$[\alpha]_D^{20} = -13.5$ (c 1, $CHCl_3$)

Source of chirality: enzymatic diastereoselective
hydrolysis

Absolute configuration: (2R,3R)



N-Formyl-D-allo-isoleucine-benzyl ester

D.e. = 98% (HPLC)



$[\alpha]_D^{20} = -7.3$ (c 1, $CHCl_3$)

Source of chirality: enzymatic diastereoselective
hydrolysis

Absolute configuration: (2R,3R)

Mara Cambiè,* Paola D'Arrigo, Ezio Fasoli, Stefano Servi,
Davide Tessaro, Francesco Canevotti and Lucio Del Corona

Tetrahedron: Asymmetry 14 (2003) 3189



N-Acetyl-D-allo-isoleucine-benzyl ester

D.e. >98% (HPLC)


$[\alpha]_D^{20} = -13.6$ (*c* 1, CHCl₃)

Source of chirality: enzymatic diastereoselective hydrolysis

Absolute configuration: (2*R*,3*R*)

Mara Cambiè,* Paola D'Arrigo, Ezio Fasoli, Stefano Servi,
Davide Tessaro, Francesco Canevotti and Lucio Del Corona

Tetrahedron: Asymmetry 14 (2003) 3189



D-Allo-isoleucine-benzyl ester hydrochloride

D.e. = 98% (HPLC)



$[\alpha]_D^{20} = -25$ (*c* 2, H₂O)

Source of chirality: crystallisation

Absolute configuration: (2*R*,3*R*)

Mara Cambiè,* Paola D'Arrigo, Ezio Fasoli, Stefano Servi,
Davide Tessaro, Francesco Canevotti and Lucio Del Corona

Tetrahedron: Asymmetry 14 (2003) 3189



D-Allo-isoleucine

D.e. = 98% (HPLC)


$[\alpha]_D^{20} = -36.2$ (*c* 2, 5N HCl)

Source of chirality: enzymatic diastereoselective hydrolysis

Absolute configuration: (2*R*,3*R*)

Pierangela Ciuffreda, Laura Alessandrini, Giancarlo Terraneo
and Enzo Santaniello*

Tetrahedron: Asymmetry 14 (2003) 3197




(2*R*)-2-Hydroxypropyl benzoate

Ee = 61%

$[\alpha]_D^{25} = -12.9$ (*c* 1, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: 2*R*




C₁₃H₂₀O₂S
(R)-(+)-1-Butylthio-3-phenoxypropan-2-ol

Ee = 99%

[α]_D²² = +4.5 (c 1.76, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: R




C₁₄H₂₂O₂S
(R)-(+)-1-Butylthio-3-(4-methylphenoxy)propan-2-ol

Ee = 85%

[α]_D²² = +4.9 (c 1.0, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: R




C₁₄H₂₂O₂S
(R)-(+)-1-Butylthio-3-(3-methylphenoxy)propan-2-ol

Ee = 86%

[α]_D²² = +5.8 (c 1.98, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: R




C₁₄H₂₂O₂S
(R)-(+)-1-Butylthio-3-(2-methylphenoxy)propan-2-ol

Ee = 43%

[α]_D²² = +1.6 (c 0.54, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: R


 $C_{13}H_{19}ClO_2S$

(R)-(+)-1-Butylthio-3-(4-chlorophenoxy)propan-2-ol

Ee = 38%

 $[\alpha]_D^{22} = +3.6$ (*c* 2.95, CHCl₃)

Source of chirality: enzymatic kinetic resolution


Absolute configuration: *R* $C_{11}H_{16}O_2S$

(R)-(+)-1-Ethylthio-3-phenoxypropan-2-ol

Ee = 47%

 $[\alpha]_D^{22} = +2.9$ (*c* 2.09, CHCl₃)

Source of chirality: enzymatic kinetic resolution


Absolute configuration: *R* $C_{12}H_{18}O_2S$

(R)-(+)-1-Ethylthio-3-(4-methylphenoxy)propan-2-ol

Ee = 22%

 $[\alpha]_D^{22} = +1.6$ (*c* 1.82, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: *R* $C_{13}H_{20}O_2S$


(R)-(+)-1-tert-Butylthio-3-phenoxypropan-2-ol

Ee = 24%

 $[\alpha]_D^{22} = +1.6$ (1.90, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: *R*


 $C_{15}H_{22}O_3S$

(S)-(+)-1-Butylthio-3-phenoxypropan-2-ol acetate

Ee = 91%

 $[\alpha]_D^{22} = +6.4$ (*c* 1.72, CHCl₃)

Source of chirality: enzymatic kinetic resolution


Absolute configuration: *S* $C_{16}H_{24}O_3S$

(S)-(+)-1-Butylthio-3-(4-methylphenoxy)propan-2-ol acetate

Ee = 67%

 $[\alpha]_D^{24} = +5.0$ (*c* 1.79, CHCl₃)

Source of chirality: enzymatic kinetic resolution


Absolute configuration: *S* $C_{16}H_{24}O_3S$

(S)-(+)-1-Butylthio-3-(3-methylphenoxy)propan-2-ol acetate

Ee = 82%

 $[\alpha]_D^{24} = +6.1$ (*c* 1.81, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: *S* $C_{16}H_{24}O_3S$


(S)-(+)-1-Butylthio-3-(2-methylphenoxy)propan-2-ol acetate

Ee = 82%

 $[\alpha]_D^{24} = +13.9$ (*c* 0.54, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: *S*


 $C_{15}H_{21}ClO_3S$

(S)-(+)-1-Butylthio-3-(4-chlorophenoxy)propan-2-ol acetate

Ee = 73%

 $[\alpha]_D^{24} = +4.6$ (*c* 1.83, CHCl₃)

Source of chirality: enzymatic kinetic resolution


Absolute configuration: *S* $C_{13}H_{18}O_3S$

(S)-(+)-1-Ethylthio-3-phenoxypropan-2-ol acetate

Ee = 83%

 $[\alpha]_D^{24} = +5.6$ (*c* 1.70, CHCl₃)

Source of chirality: enzymatic kinetic resolution


Absolute configuration: *S* $C_{14}H_{20}O_3S$

(S)-(+)-1-Ethylthio-3-(4-methylphenoxy)propan-2-ol acetate

Ee = 24%

 $[\alpha]_D^{24} = +3.5$ (*c* 1.70, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: *S* $C_{15}H_{22}O_3S$


(S)-(+)-1-tert-Butylthio-3-phenoxypropan-2-ol acetate

Ee = 67%

 $[\alpha]_D^{22} = +4.8$ (*c* 1.60, CHCl₃)

Source of chirality: enzymatic kinetic resolution

Absolute configuration: *S*



C₁₆H₁₇NO₂


(R)-(-)-2-(Acetamido)-2'-hydroxy-6,6'-dimethyl-1,1'-biphenyl

Ee >99%

[α]_D²³ = -7.9 (c 0.5, THF)

Source of chirality: synthesized

Absolute configuration: R



C₁₈H₂₁NO₂


(R)-(-)-2-(Acetamido)-2'-hydroxy-4,4',6,6'-tetramethyl-1,1'-biphenyl

Ee >99%

[α]_D²³ = -7.6 (c 0.5, THF)

Source of chirality: synthesized

Absolute configuration: R



C₁₇H₁₆F₃NO₄S


(R)-(-)-2-(Acetamido)-2'-(trifluoromethylsulfonyloxy)-6,6'-dimethyl-1,1'-biphenyl

Ee >99%

[α]_D²³ = -36.3 (c 0.5, THF)

Source of chirality: synthesized

Absolute configuration: R



C₁₉H₂₀F₃NO₄S

(R)-(-)-2-(Acetamido)-2'-(trifluoromethylsulfonyloxy)-4,4',6,6'-tetramethyl-1,1'-biphenyl

Ee >99%

[α]_D²³ = -38.4 (c 0.5, THF)


Source of chirality: synthesized

Absolute configuration: R




(R)-(-)-2-(Acetamido)-2'-(diphenylphosphinyl)-6,6'-dimethyl-1,1'-biphenyl

Ee >99%
[α]_D²³ = -130.4 (c 0.5, THF)
Source of chirality: synthesized
Absolute configuration: R




(R)-(-)-2-(Acetamido)-2'-(diphenylphosphinyl)-4,4',6,6'-tetramethyl-1,1'-biphenyl

Ee >99%
[α]_D²³ = -94.3 (c 0.5, THF)
Source of chirality: synthesized
Absolute configuration: R




(R)-(-)-2-Amino-2'-(diphenylphosphinyl)-6,6'-dimethyl-1,1'-biphenyl

Ee >99%
[α]_D²⁴ = -87.9 (c 0.5, THF)
Source of chirality: synthesized
Absolute configuration: R



(R)-(-)-2-Amino-2'-(diphenylphosphinyl)-4,4',6,6'-tetramethyl-1,1'-biphenyl

Ee >99%
[α]_D²³ = -78.7 (c 0.5, THF)
Source of chirality: synthesized
Absolute configuration: R



C₂₆H₂₄NP


(R)-(-)-2-Amino-2'-(diphenylphosphino)-6,6'-dimethyl-1,1'-biphenyl

Ee >99%

[α]_D²³ = -83.9 (*c* 0.5, THF)

Source of chirality: synthesized

Absolute configuration: *R*



C₂₈H₂₈NP


(R)-(-)-2-Amino-2'-(diphenylphosphino)-4,4',6,6'-tetramethyl-1,1'-biphenyl

Ee >99%

[α]_D²³ = -78.4 (*c* 0.5, THF)

Source of chirality: synthesized

Absolute configuration: *R*



C₃₃H₂₉N₂OP


(R)-(-)-2-(6-Methyl-2-pyridinylcarboxamido)-2'-(diphenylphosphino)-6,6'-dimethyl-1,1'-biphenyl

Ee >99%

[α]_D²³ = -176.6 (*c* 0.5, THF)

Source of chirality: synthesized

Absolute configuration: *R*



C₃₅H₃₃N₂OP


(R)-(-)-2-(6-Methyl-2-pyridinylcarboxamido)-2'-(diphenylphosphino)-4,4',6,6'-tetramethyl-1,1'-biphenyl

Ee >99%

[α]_D²³ = -180.9 (*c* 0.5, THF)

Source of chirality: synthesized

Absolute configuration: *R*




C₁₉H₂₀O₂
(S)-7,7'-Dimethoxy-1,1'-spirobiindane

E.e. = 100%

[α]_D²⁵ = -40 (c 0.5, CH₂Cl₂)

Source of chirality: chiral resolution

Absolute configuration: S




C₁₉H₁₈Br₂O₂
(S)-4,4'-Dibromo-7,7'-dimethoxy-1,1'-spirobiindane

E.e. = 100%

[α]_D²⁵ = +26 (c 0.5, CH₂Cl₂)

Source of chirality: chiral resolution

Absolute configuration: S




C₁₇H₁₄Br₂O₂
(S)-4,4'-Dibromo-7,7'-dihydroxy-1,1'-spirobiindane

E.e. = 100%

[α]_D²⁵ = +184 (c 0.5, CH₂Cl₂)

Source of chirality: chiral resolution

Absolute configuration: S




C₃₁H₂₈O₂
(S)-4,4'-Diphenyl-7,7'-dimethoxy-1,1'-spirobiindane

E.e. = 100%

[α]_D²⁵ = +6 (c 0.5, CH₂Cl₂)

Source of chirality: chiral resolution

Absolute configuration: S




C₂₉H₂₄O₂
(S)-4,4'-Diphenyl-7,7'-dihydroxy-1,1'-spirobiindane

E.e. = 100%

[α]_D²⁵ = +142 (*c* 0.5, CH₂Cl₂)

Source of chirality: chiral resolution

Absolute configuration: *S*




C₁₉H₂₀O₄
(S)-4,4'-Dimethoxy-7,7'-dihydroxy-1,1'-spirobiindane

E.e. = 100%

[α]_D²⁵ = -16 (*c* 0.5, CH₂Cl₂)

Source of chirality: chiral resolution

Absolute configuration: *S*




C₁₉H₁₈Br₂NO₂P
(S)-O,O'-[4,4'-Dibromo-1,1'-spirobiindane-7,7'-diyl]-N,N-dimethylphosphoramidite

E.e. = 100%

[α]_D²⁵ = -208 (*c* 0.5, CH₂Cl₂)

Source of chirality: chiral resolution

Absolute configuration: *S*




C₃₁H₂₈NO₂P
(S)-O,O'-[4,4'-Diphenyl-1,1'-spirobiindane-7,7'-diyl]-N,N-dimethylphosphoramidite

E.e. = 100%

[α]_D²⁵ = -216 (*c* 0.5, CH₂Cl₂)

Source of chirality: chiral resolution

Absolute configuration: *S*





(*S*)-*O,O'*-[4,4'-Dimethoxy-1,1'-spirobiindane-7,7'-diyl]-*N,N*-dimethylphosphoramidite

E.e. = 100%

$[\alpha]_D^{25} = -220$ (*c* 0.5, CH_2Cl_2)

Source of chirality: chiral resolution

Absolute configuration: *S*





(*1S,2R,5R,7S,9R*)-5-Benzoyl-10,10-dimethyl-4-oxa-6-thiatricyclo[7.1.1.0^2,7]undecane

Dr >99% (NMR)

$[\alpha]_D^{25} = -68.4$

Source of chirality: (-)-myrtenal

Absolute configuration: (1*S*,2*R*,5*R*,7*S*,9*R*)




(*1S,2R,5R,7S,9R*)-5-[(1'*S*)-1'-Hydroxy-1'-phenyl-1'-ethyl]-10,10-dimethyl-4-oxa-6-thiatricyclo[7.1.1.0^2,7]undecane

Dr >99% (NMR)

$[\alpha]_D^{25} = -62.4$

Source of chirality: (-)-myrtenal

Absolute configuration: (1*S*,2*R*,5*R*,7*S*,9*R*,1'*S*)




(*1S,2R,5R,7S,9R*)-5-[(1'*S*)-1'-Hydroxy-1'-phenyl-1'-propyl]-10,10-dimethyl-4-oxa-6-thiatricyclo[7.1.1.0^2,7]undecane

Dr >99% (NMR)

$[\alpha]_D^{25} = -72.8$

Source of chirality: (-)-myrtenal

Absolute configuration: (1*S*,2*R*,5*R*,7*S*,9*R*,1'*S*)



C₂₁H₃₀O₂S


(1S,2R,5R,7S,9R)-5-[(1'S)-1'-Hydroxy-2'-methyl-1'-phenyl-1'-propyl]-10,10-dimethyl-4-oxa-6-thiatricyclo[7.1.1.0^2.7]undecane

Dr >99% (NMR)

[α]_D²⁵ = -68.1

Source of chirality: (-)-myrtenal

Absolute configuration: (1S,2R,5R,7S,9R,1'S)



C₂₅H₃₀O₂S


(1S,2R,5R,7S,9R)-5-[(1'S)-1'-Hydroxy-1',2'-diphenyl-1'-ethyl]-10,10-dimethyl-4-oxa-6-thiatricyclo[7.1.1.0^2.7]undecane

Dr >99% (NMR)

[α]_D²⁴ = -86.6

Source of chirality: (-)-myrtenal

Absolute configuration: (1S,2R,5R,7S,9R,1'S)



C₂₂H₃₂O₂S


(1S,2R,5R,7S,9R)-5-[(1'S)-1'-Hydroxy-3'-methyl-1'-phenyl-1'-butyl]-10,10-dimethyl-4-oxa-6-thiatricyclo[7.1.1.0^2.7]undecane

Dr >99% (NMR)

[α]_D²⁰ = -68.8

Source of chirality: (-)-myrtenal

Absolute configuration: (1S,2R,5R,7S,9R,1'S)



C₂₀H₂₆O₂S

(1S,2R,5R,7S,9R)-5-[(1'S)-1'-Hydroxy-1'-phenyl-2'-propen-1'-yl]-10,10-dimethyl-4-oxa-6-thiatricyclo[7.1.1.0^2.7]undecane

Dr >99% (NMR)


[α]_D²⁵ = -68.1

Source of chirality: (-)-myrtenal

Absolute configuration: (1S,2R,5R,7S,9R,1'S)

María Elena Vargas-Díaz, Luis Chacón-García, Pedro Velázquez,
Joaquín Tamariz, Pedro Joseph-Nathan and L. Gerardo Zepeda*

Tetrahedron: Asymmetry 14 (2003) 3225



C₂₆H₂₈O₂S

(1*S*,2*R*,5*R*,7*S*,9*R*)-5-[(1'*S*)-1'-Hydroxy-1',3'-diphenyl-2'-propyn-1'-yl]-10,10-dimethyl-4-oxa-6-thiatricyclo[7.1.1.0^{2,7}]undecane

Dr >99% (NMR)


[α]_D²⁵ = -27.1

Source of chirality: (-)-myrtenal

Absolute configuration: (1*S*,2*R*,5*R*,7*S*,9*R*,1'i'S)

María Elena Vargas-Díaz, Luis Chacón-García, Pedro Velázquez,
Joaquín Tamariz, Pedro Joseph-Nathan and L. Gerardo Zepeda*

Tetrahedron: Asymmetry 14 (2003) 3225



C₁₈H₂₄O₂S

(1*S*,2*R*,5*R*,7*S*,9*R*)-5-[(*S*)-1'-Hydroxymethylphenyl]-10,10-dimethyl-4-oxa-6-thiatricyclo[7.1.1.0^{2,7}]undecane

Dr >99% (NMR)


[α]_D²⁵ = -45.9

Source of chirality: (-)-myrtenal

Absolute configuration: (1*S*,2*R*,5*R*,7*S*,9*R*,*S*)

María Elena Vargas-Díaz, Luis Chacón-García, Pedro Velázquez,
Joaquín Tamariz, Pedro Joseph-Nathan and L. Gerardo Zepeda*

Tetrahedron: Asymmetry 14 (2003) 3225



C₉H₁₂O₂

(*S*)-(+)-2-Phenylpropane-1,2-diol

Ee >99%


[α]_D²³ = +5.7

Source of chirality: asymmetric synthesis

Absolute configuration: (*S*)

María Elena Vargas-Díaz, Luis Chacón-García, Pedro Velázquez,
Joaquín Tamariz, Pedro Joseph-Nathan and L. Gerardo Zepeda*

Tetrahedron: Asymmetry 14 (2003) 3225



C₁₀H₁₄O₂

(*S*)-(-)-2-Phenylbutane-1,2-diol

Ee >98%


[α]_D²⁵ = -7.2

Source of chirality: asymmetric synthesis

Absolute configuration: (*S*)

María Elena Vargas-Díaz, Luis Chacón-García, Pedro Velázquez,
Joaquín Tamariz, Pedro Joseph-Nathan and L. Gerardo Zepeda*

Tetrahedron: Asymmetry 14 (2003) 3225



(*S*)-(-)-3-Methyl-2-phenylbutane-1,2-diol

Ee >98%


$[\alpha]_D^{20} = -19.5$

Source of chirality: asymmetric synthesis

Absolute configuration: (*S*)

María Elena Vargas-Díaz, Luis Chacón-García, Pedro Velázquez,
Joaquín Tamariz, Pedro Joseph-Nathan and L. Gerardo Zepeda*

Tetrahedron: Asymmetry 14 (2003) 3225



(*S*)-(-)-2-Phenylbut-3-ene-1,2-diol

Ee >98%


$[\alpha]_D^{20} = -43.4$

Source of chirality: asymmetric synthesis

Absolute configuration: (*S*)

María Elena Vargas-Díaz, Luis Chacón-García, Pedro Velázquez,
Joaquín Tamariz, Pedro Joseph-Nathan and L. Gerardo Zepeda*

Tetrahedron: Asymmetry 14 (2003) 3225



(*S*)-(+)-2,4-Diphenylbut-3-yne-1,2-diol

Ee >99%


$[\alpha]_D^{20} = +11.0$

Source of chirality: asymmetric synthesis

Absolute configuration: (*S*)

María Elena Vargas-Díaz, Luis Chacón-García, Pedro Velázquez,
Joaquín Tamariz, Pedro Joseph-Nathan and L. Gerardo Zepeda*

Tetrahedron: Asymmetry 14 (2003) 3225



(*S*)-(+)-2,4-Diphenylbutane-1,2-diol

Ee >99%


$[\alpha]_D^{23} = +10.6$

Source of chirality: asymmetric synthesis

Absolute configuration: (*S*)

María Elena Vargas-Díaz, Luis Chacón-García, Pedro Velázquez,
Joaquín Tamariz, Pedro Joseph-Nathan and L. Gerardo Zepeda*

Tetrahedron: Asymmetry 14 (2003) 3225



C₈H₁₀O₂
(S)-(+)-1-Phenylethane-1,2-diol

Ee >99%


[α]_D²³ = +38.6

Source of chirality: asymmetric synthesis

Absolute configuration: (S)

Trisha R. Hoover and Shawn R. Hitchcock*

Tetrahedron: Asymmetry 14 (2003) 3233



C₁₉H₂₀N₂O₄
(4R,5S,6R)-3,4,5,6-Tetrahydro-4,5-dimethyl-3-(2-phenoxyacetyl)-6-phenyl-2H-1,3,4-oxadiazin-2-one


[α]_D²⁵ = -41.8 (c 1.14, methanol)

Source of chirality: (1R,2S)-ephedrine

Absolute configuration: (4R,5S,6R)

Trisha R. Hoover and Shawn R. Hitchcock*

Tetrahedron: Asymmetry 14 (2003) 3233



C₂₀H₂₂N₂O₅
(4R,5S,6R)-3,4,5,6-Tetrahydro-3-[2-(4-methoxyphenoxy)acetyl]-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one


[α]_D²⁵ = -40.5 (c 1.66, methanol)

Source of chirality: (1R,2S)-ephedrine

Absolute configuration: (4R,5S,6R)

Trisha R. Hoover and Shawn R. Hitchcock*

Tetrahedron: Asymmetry 14 (2003) 3233




C₁₄H₁₈N₂O₄
(4R,5S,6R)-3-(2-Methoxyacetyl)-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one


[α]_D²⁵ = -70.9 (c 1.86, methanol)

Source of chirality: (1R,2S)-ephedrine

Absolute configuration: (4R,5S,6R)

 $C_{20}H_{23}N_2O_4$


(4R,5S,6R)-3-(2-Benzylxyacetyl)-3,4,5,6-tetrahydro-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one

 $[\alpha]_D^{25} = -55.7$ (*c* 2.15, methanol)Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: (4*R*,5*S*,6*R*) $C_{26}H_{26}N_2O_5$

(2'S,3'R,4R,5S,6R)-3-(3-hydroxy-2-phenoxy-3-phenylpropionyl)-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one

 $[\alpha]_D^{25} = -6.0$ (*c* 2.46, methanol)Source of chirality: (1*R*,2*S*)-ephedrine


Absolute configuration: (2'S,3'R,4R,5S,6R)

 $C_{26}H_{26}N_2O_5Cl$

(2'S,3'R,4R,5S,6R)-3-[3-(4-Chlorophenyl)-3-hydroxy-2-phenoxypropionyl]-4,5,6-tetrahydro-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one

 $[\alpha]_D^{25} = -1.4$ (*c* 2.22, methanol)Source of chirality: (1*R*,2*S*)-ephedrine







Absolute configuration: (2'S,3'R,4R,5S,6R)


 $C_{27}H_{28}N_2O_5$

(2'S,3'R,4R,5S,6R)-3-[3-hydroxy-2-(4-methoxyphenyl)-2-phenoxypropionyl]-4,5,6-tetrahydro-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one

 $[\alpha]_D^{25} = -20.8$ (*c* 2.29, methanol)Source of chirality: (1*R*,2*S*)-ephedrine

Absolute configuration: (2'S,3'R,4R,5S,6R)


 $[\alpha]_D^{25} = +10.3$ (*c* 2.00, methanol)
Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: (2'*S*,3'*R*,4*R*,5*S*,6*R*)(2'*S*,3'*R*,4*R*,5*S*,6*R*)-3,4,5,6-Tetrahydro-3-(3-hydroxy-3-naphthalen-2-yl-2-phenoxy-propionyl)-4,5-dimethyl-6-phenyl-2*H*-1,3,4-oxadiazin-2-one
 $[\alpha]_D^{25} = -6.0$ (*c* 1.28, methanol)
Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: (2'*S*,3'*R*,4*R*,5*S*,6*R*)(2'*S*,3'*R*,4*R*,5*S*,6*R*)-3,4,5,6-Tetrahydro-3-(3-hydroxy-2-phenoxy-3-m-tolylpropionyl)-4,5-dimethyl-6-phenyl-2*H*-1,3,4-oxadiazin-2-one
 $[\alpha]_D^{25} = -41.3$ (*c* 1.73, ethanol)
Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: 2*S*,3*R*(+)-(2*S*,3*R*)-3-Hydroxy-2-phenoxy-3-phenylpropionic acid
 $[\alpha]_D^{25} = -13.7$ (*c* 2.10, methanol)
Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: (2'*S*,3'*R*,4*R*,5*S*,6*R*)(2'*S*,3'*R*,4*R*,5*S*,6*R*)-3,4,5,6-Tetrahydro-3-[3-hydroxy-2-(4-methoxyphenoxy)-3-phenylpropionyl]-4,5-dimethyl-6-phenyl-2*H*-1,3,4-oxadiazin-2-one




$C_{27}H_{28}N_2O_6Cl$
(2'S,3'R,4R,5S,6R)-3-[3-(4-Chlorophenyl)-3-hydroxy-2-(4-methoxyphenoxy)propionyl]-3,4,5,6-tetrahydro-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one

$[\alpha]_D^{25} = -6.5$ (*c* 2.20, methanol)

Source of chirality: (1*R*,2*S*)-ephedrine

Absolute configuration: (2'S,3'R,4R,5S,6*R*)




$C_{28}H_{30}N_2O_6$
(2'S,3'R,4S,5S,6R)-3,4,5,6-Tetrahydro-3-[3-Hydroxy-2-(4-methoxyphenoxy)-3-(4-methoxyphenyl)propionyl]-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one

$[\alpha]_D = -14.5$ (*c* 2.58, methanol)

Source of chirality: (1*R*,2*S*)-ephedrine

Absolute configuration: (2'S,3'R,4R,5S,6*R*)




$C_{31}H_{30}N_2O_6$
(2'S,3'R,4R,5S,6R)-3,4,5,6-Tetrahydro-3-[3-hydroxy-2-(4-methoxyphenoxy)-3-naphthalen-2-yl-propionyl]-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one

$[\alpha]_D^{25} = +2.2$ (*c* 1.92, methanol)

Source of chirality: (1*R*,2*S*)-ephedrine

Absolute configuration: (2'S,3'R,4R,5S,6*R*)




$C_{28}H_{30}N_2O_6$
(2'S,3'R,4R,5S,6R)-3,4,5,6-Tetrahydro-3-[3-hydroxy-2-(4-methoxyphenoxy)-3-m-tolylpropionyl]-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one


$[\alpha]_D^{25} = -10.4$ (*c* 2.71, methanol)

Source of chirality: (1*R*,2*S*)-ephedrine


Absolute configuration: (2'S,3'R,4R,5S,6*R*)

 $C_{21}H_{24}N_2O_5$


(2'S,3'R,4R,5S,6R)-3,4,5,6-Tetrahydro-3-(3-hydroxy-2-methoxy-3-phenylpropionyl)-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one

 $[\alpha]_D^{25} = -60.8$ (*c* 1.98, methanol)Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: (2'*S*,3'*R*,4*R*,5*S*,6*R*) $C_{21}H_{24}N_2O_5Cl$

(2'S,3'R,4R,5S,6R)-3-[3-(4-Chlorophenyl)-3-hydroxy-2-methoxypropionyl]-3,4,5,6-tetrahydro-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one



 $[\alpha]_D^{25} = -44.1$ (*c* 2.45, methanol)Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: (2'*S*,3'*R*,4*R*,5*S*,6*R*) $C_{22}H_{26}N_2O_6$

(2'S,3'R,4R,5S,6R)-3,4,5,6-Tetrahydro-3-[3-hydroxy-2-methoxy-3-(4-methoxyphenyl)propionyl]-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one

 $[\alpha]_D^{25} = -41.8$ (*c* 2.33, methanol)Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: (2'*S*,3'*R*,4*R*,5*S*,6*R*) $C_{25}H_{26}N_2O_5$

(2'S,3'R,4R,5S,6R)-3,4,5,6-Tetrahydro-3-(3-hydroxy-2-methoxy-3-naphthalen-2-yl-propionyl)-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one


 $[\alpha]_D^{25} = -56.9$ (*c* 1.77, methanol)Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: (2'*S*,3'*R*,4*R*,5*S*,6*R*)




(2'S,3'R,4R,5S,6R)-3,4,5,6-Tetrahydro-3-(3-hydroxy-2-methoxy-3-m-tolylpropionyl)-4,5-dimethyl-6-phenyl-2H-1,3,4-oxadiazin-2-one

 $[\alpha]_D^{25} = -28.6$ (*c* 2.28, methanol)Source of chirality: (1*R*,2*S*)-ephedrineAbsolute configuration: (2'*S*,3'*R*,4*R*,5*S*,6*R*)


Bruce A. Ellsworth,* Abigail G. Doyle, Manorama Patel,
Janet Caceres-Cortes, Wei Meng, Prashant P. Deshpande,
Annie Pullockaran and William N. Washburn

(1*S*)-2,3,4,6-Tetra-*O*-benzyl-1*C*-phenyl-1-deoxyglucose $[\alpha]_D^{25} = +11.1$ (*c* 0.38, $CHCl_3$)De >95% (1H NMR)Source of chirality: tetra-*O*-benzyl-D-gluconolactone
and asymmetric reduction at the anomeric centerAbsolute configuration: (1*S*,2*S*,3*R*,4*R*,5*R*)

Bruce A. Ellsworth,* Abigail G. Doyle, Manorama Patel,
Janet Caceres-Cortes, Wei Meng, Prashant P. Deshpande,
Annie Pullockaran and William N. Washburn

(1*R*)-2,3,4,6-Tetra-*O*-benzyl-1*C*-phenyl-1-deoxyglucose $[\alpha]_D^{25} = +95.5$ (*c* 0.02, $CDCl_3$)De >95% (1H NMR)Source of chirality: tetra-*O*-benzyl-D-gluconolactone
and asymmetric reduction at the anomeric centerAbsolute configuration: (1*R*,2*S*,3*R*,4*R*,5*R*)

Paulo Marcos Donate,* Daniel Frederico, Rosangela da Silva,
Mauricio Gomes Constantino, Gino Del Ponte
and Pierina Sueli Bonatto*

4-[(Methoxymethoxy)methyl]-3-phenyldihydrofuran-2-(3*H*)-one

E.e. = 98.5%

 $[\alpha]_D^{25} = -7.3$ (*c* 0.5, MeOH)Source of chirality: (*S*)-BINAP-rhodium complex

Paulo Marcos Donate,* Daniel Frederico, Rosangela da Silva,
Mauricio Gomes Constantino, Gino Del Ponte
and Pierina Sueli Bonatto*


Tetrahedron: Asymmetry 14 (2003) 3253

E.e. = 97%

$[\alpha]_D^{25} = +16.4$ (*c* 15.2, EtOH)

Source of chirality: (*R*)-BINAP–rhodium complex

Absolute configuration (*2R*)



(*2R*)-2-Methyl-succinic acid